Antibody could offer benefit in patients with atopic dermatitis
The anti-interleukin-13 monoclonal antibody cendakimab may be safe and effective in adult patients with atopic dermatitis.
In a phase II clinical trial, published in JAMA Dermatology, researchers randomly assigned 221 patients with atopic dermatitis to receive either subcutaneous cendakimab or placebo at dosages of 360 mg every two weeks, 720 mg every two weeks or 720 mg once per week.
After a follow-up of 16 weeks, the researchers found that the patients who received 720 mg of cendakimab once per week had a greater reduction in their eczema severity compared with those who received 720 mg of cendakimab every two weeks and those who received placebo. The patients who received 360 mg of cendakimab every two weeks showed a comparable treatment effect as those who received 720 mg of the medication once per week.
The researchers reported that the treatment-related adverse events were mostly mild to moderate. The findings supported the use of the interleukin-13 inhibitor cendakimab in patients with atopic dermatitis.
Read more: JAMA Dermatology
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.